Foundations Investment Advisors LLC Invests $322,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Foundations Investment Advisors LLC bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 742 shares of the pharmaceutical company’s stock, valued at approximately $322,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VRTX. Venturi Wealth Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 1.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock valued at $933,000 after acquiring an additional 24 shares during the last quarter. Nicholas Hoffman & Company LLC. boosted its holdings in Vertex Pharmaceuticals by 3.9% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after purchasing an additional 24 shares during the last quarter. Arthur M. Cohen & Associates LLC grew its position in Vertex Pharmaceuticals by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after purchasing an additional 25 shares during the period. Baystate Wealth Management LLC raised its stake in Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. Finally, Vestor Capital LLC lifted its holdings in Vertex Pharmaceuticals by 10.8% in the fourth quarter. Vestor Capital LLC now owns 256 shares of the pharmaceutical company’s stock valued at $104,000 after acquiring an additional 25 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Up 1.0 %

Shares of VRTX opened at $445.21 on Friday. The company’s fifty day moving average is $409.75 and its 200 day moving average is $404.29. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $320.01 and a fifty-two week high of $448.40. The stock has a market capitalization of $114.89 billion, a PE ratio of 28.89, a P/E/G ratio of 2.13 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last posted its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The firm had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.58 billion. During the same period in the previous year, the firm posted $2.67 EPS. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of several recent research reports. Wolfe Research began coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price objective on the stock. Truist Financial boosted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. HC Wainwright reaffirmed a “buy” rating and issued a $462.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. StockNews.com upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Finally, Robert W. Baird cut shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price on the stock. in a research note on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $432.18.

View Our Latest Analysis on Vertex Pharmaceuticals

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Further Reading

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.